Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

p53 from basic research to clinical applications.

O Tominaga1, R Hamelin, Y Remvikos

  • 1Laboratory of Radiopathology, Institut Curie, Paris, France.

Critical Reviews in Oncogenesis
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain.

The EMBO journal·1995
Same author

Rapamycin, wortmannin, and the methylxanthine SQ20006 inactivate p70s6k by inducing dephosphorylation of the same subset of sites.

The Journal of biological chemistry·1995
Same author

Recurrent and novel LDL receptor gene mutations causing heterozygous familial hypercholesterolemia in La Habana.

Human genetics·1995
Same author

Structure and promoter characterization of the human stromelysin-3 gene.

The Journal of biological chemistry·1995
Same author

Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas.

Oncogene·1995
Same author

Molecular analysis of genetic changes in ependymomas.

Genes, chromosomes & cancer·1995
Same journal

Transcription Factor and Tumorigenesis: Perspectives and Concluding Remarks.

Critical reviews in oncogenesis·2026
Same journal

Review Article: Intratumoral Immunotherapy: Old Discoveries and Recent Developments in Sarcomas.

Critical reviews in oncogenesis·2026
Same journal

Review Article: Dynamin-Related Protein 1 in Cancer Progression: Mechanisms and Implications.

Critical reviews in oncogenesis·2026
Same journal

Review Article: EZH2 in Pancreatic Cancer: Epigenetic Driver and Therapeutic Target.

Critical reviews in oncogenesis·2026
Same journal

Review Article: YY2 in Tumor Regulation: Core Mechanisms and Functional Networks.

Critical reviews in oncogenesis·2026
Same journal

Review Article: Decoding the Role of PBX3 in Cancer: Molecular Mechanisms and Therapeutic Strategies.

Critical reviews in oncogenesis·2026
See all related articles

Mutations in the TP53 tumor suppressor gene are common in human cancers, often leading to aggressive disease. Monitoring these TP53 alterations is crucial for therapeutic trials and understanding cancer predisposition.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • TP53 gene mutations and 17p allele loss are frequent in human cancers.
  • The p53 protein, encoded by TP53, regulates cell proliferation and suppresses tumors.
  • Mutant TP53 can promote cell transformation, unlike its wild-type counterpart.

Purpose of the Study:

  • To review the role of TP53 alterations in human carcinogenesis.
  • To discuss the functional consequences of TP53 mutations.
  • To highlight the clinical implications of TP53 alterations in cancer treatment and predisposition.

Main Methods:

  • Literature review of TP53 gene mutations and their impact.
  • Analysis of TP53 protein function in wild-type and mutant forms.
  • Correlation of TP53 alterations with cancer phenotypes and therapeutic strategies.

Related Experiment Videos

Main Results:

  • TP53 mutations exhibit diverse biological activities, from promoting transformation to loss of function.
  • Mutational spectrum of TP53 varies across cancer types, suggesting different etiological factors.
  • TP53 alterations are linked to aggressive cancer phenotypes and poorer prognoses.
  • Germline TP53 mutations predispose individuals to multiple neoplasms.

Conclusions:

  • TP53 alterations are critical drivers of cancer progression and aggressiveness.
  • Monitoring TP53 status is essential for clinical trials and patient management.
  • Understanding TP53 germline mutations aids in defining follow-up for at-risk individuals.